Happiness is an empty beach, the wind in your ears, your best friend by your side, and 0/8 feet on the ground

#ENZARAD #ProstateCancer #pcsm @ANZUPtrials @TrialsCentre @cancertrials_ie @DanaFarber @eortc @TROGfightcancer

How could DASL-HiCaP influence treatment decisions for patients with high-risk #ProstateCancer? Following #ESMO26, Dr. Tamim Niazi shares his perspective on current treatment and where darolutamide could fit into future practice. ▶️ Watch the full video: mirrorsmed.org/a2p-pca-esmo-… @OncoAlert @niazi_Dr7

💔💔💔 merriam-webster.com/dictiona…

🔬 Can adding an androgen receptor inhibitor to ADT and radiotherapy improve metastasis-free survival in very high-risk localised prostate cancer? New Phase 3 interim results from DASL-HiCaP suggest a significant benefit. 📊 LBA4 – DASL-HiCaP (ANZUP1801): Darolutamide with ADT and definitive or salvage locoregional radiotherapy cslide.ctimeetingtech.com/es… Darolutamide added to ADT and locoregional radiotherapy significantly improved metastasis-free survival in patients with very high-risk localised or biochemically persistent/recurrent prostate cancer. At four years, metastasis-free survival was 95% versus 88% with placebo (HR 0.42; p=0.0001). ✅ These findings support treatment intensification, although longer follow-up is needed to establish whether this benefit translates into improved overall survival. #ProstateCancer @niazi_Dr7, @Prof_IanD, @ChrisSweens1, @AlisonZhangMBBS, @seanmmcbride, @DocJarad, @DavePryorRO, @MartinStockler @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Voting is compulsory in Australia. It sometimes feels a bit inconvenient or like choosing the least worst option, but if you don’t vote then you have no right to complain if bad people get elected. Choosing not to vote when your democracy is crumbling would be a strange decision.

‼️ On 134 key questions in prostate cancer care, experts reached consensus on just 44. What does that tell us about the evidence guiding treatment — and where do we need better answers? 📄 Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference 🔗 sciencedirect.com/science/ar… At #APCCC26, 144 international experts 🌐 tackled challenging clinical questions where high-level evidence remains limited. Using a modified Delphi process, 133 panellists voted on 134 questions covering high-risk localised, locally advanced and biochemically recurrent prostate cancer, including PSA persistence, PSA recurrence and treatment-related side effects. ✅ Consensus (≥75% agreement) was reached on just 44 questions (32.8%), with strong consensus (≥90%) on only seven. 👉 Where experts disagree, the need for better evidence is clear. Areas without consensus highlight important priorities for future clinical trials. @Silke_Gillessen, @AOmlin, @Prof_Nick_James, @LVM_Walz, @AOmlin, @AttardLab, @bjartell, @LoebStacy, @Tilki_De, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @VedangMurthy, @neerajaiims, @Achard_Verane, @PBlanchardMD, @lisahorvath73, @BarbaraJereczek, @fontev1, @ChrisSweens1, @AarmstrongDuke, @CharlesRyanMD, @ProfKHerrmann, @KarimFizazi, @NealShore, @himishabeltran, @HeatherChengMD, @DrRanaMcKay, @AliciaMorgansMD, @declangmurphy, @DrSpratticus, @EvanYuMD, @NehaVapiwalaMD, @drjefstathiou, @BertrandTOMBAL @OncoAlert 🚨 #ProstateCancer #APCCC26

APCCC 2026 consensus report part 1 is out! Proud to have contributed to addressing key challenges in prostate cancer care. Many thanks to Silke Gillessen, Aurelius Omlin, and all colleagues. @EUplatinum @APCCC_Lugano @OncoAlert @Silke_Gillessen @AOmlin @Prof_IanD @ChrisSweens1 @Uromigos

@APCCC_Lugano 2026 Consensus is out! 😃🥳👩‍🔬👨‍⚕️ authors.elsevier.com/sd/arti… @Silke_Gillessen @AOmlin @oncodaily @INCMNSZ_Uronco @cdanicas @UroTeragLATAM High-risk localised and locally advanced PC 🔴 PSA recurrece & persistence 🟠 Neoadjuvant systemic therapy for RT & RP 🟢 Testosterone recover & supplementation 🔵 Genetic evaluation 🟣 Bone protection

Here is the article link: authors.elsevier.com/sd/arti…

Just in @EUplatinum 👉#APCCC2026 report on high-risk localised, locally advanced & recurrent #ProstateCancer: 133 experts from across the world👉Highlights risk-adapted care & evidence gaps for trials. @APCCC_ @PCF_Science @UroToday @OncoAlert 👉link: shorturl.at/YAcnY

The value of scientific consensus is not that everyone agrees. It is that we make better decisions despite uncertainty. Honored to contribute to APCCC 2026. Congratulations to Silke, Aurelius, Fabio, and the entire team. @Silke_Gillessen @AOmlin @APCCC_Lugano @OncoAlert @EUplatinum

Fantastic paper led by from @APCCC_Lugano group about high-risk localized prostate cancer management in @EUplatinum kwnsfk27.r.eu-west-1.awstrac…

#APCCC2026: How much consensus is there in high-risk prostate cancer? 🌍 133 experts, 134 questions, and consensus on only 33%. 💡 Where do we stand on treatment intensification, PSMA-PET, radiotherapy and biomarkers? doi.org/10.1016/j.eururo.202… @OncoAlert

Amazing APCCC prostate consensus statement out today on early prostate cancer. Experts from around the world come together in Lugano to address the most contravercial issues. @Silke_Gillessen @neerajaiims @DrChoueiri @OncoAlert kwnsfk27.r.eu-west-1.awstrac…

DASL-HiCap trial #ESMO26 @myESMO @Silke_Gillessen @ANZUPtrials @APCCC_Lugano @oncodaily @OncoAlert 🔴ADT+Darolutamide+prostate/pelvis RT ⬆️ MFS-CI 🟠≠ definition "very high risk" & PSMA/PET not included 🟢Improved MFS-CI, PSA-PFS, CRPC, subsquent tx. But final analysis & OS awaited! 🔵3 studies: STAMPEDE, ENZARAD & DASL-HiCap. ≠ populations, ≠RT to pelvis, N1 benefit across trials. 🟣Good outcomes, need biomarkers

📢 #APCCC2026 at @EuropeanUrology: Everything you want to know about high-risk localised, locally advanced and recurrent #ProstateCancer. Pleased to have contributed! Read the report 👇 sciencedirect.com/science/ar… #UroOnc

🔴 Just presented at #ESMO2026: DASL-HiCaP Adding darolutamide to ADT + locoregional RT significantly improved metastasis-free survival in very high-risk localised or biochemically persistent/recurrent prostate cancer in the DASL-HiCaP trial. At 4 years: 🔹 MFS: 95% vs 88% (HR 0.42) 🔹 PSA-PFS: 91% vs 83% (HR 0.47) 🔹 PCSS: 99% vs 99% (HR 0.58) 🔹 OS: 97% vs 95% (HR 0.88) Grade ≥3 adverse events occurred in 43% with darolutamide vs 36% with placebo. Follow-up is ongoing to assess longer-term outcomes, including OS. #ESMO26 #ProstateCancer #Darolutamide #DASLHiCaP

DASL-HiCaP: Darolutamide + ADT and Radiation Therapy for Very High-Risk Localized Prostate Cancer, Phase 3 Interim Analysis. Presented by @niazi_Dr7. #ESMO26 written coverage by @zklaassen_md > bit.ly/4BpbyTr #ProstateCancer #RadOnc @myESMO

Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7 👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved ✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22) ✅increased time to subsequent hormonal therapy (HR 0.36) All clinically meaningful benefits, while OS remains immature. #ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1

#ESMO26 DASL-HiCaP Presidential Discussant -- @Silke_Gillessen Differences in BL risk and pt selection may explain variation in treatment effects for STAMPEDE M0, ENZARAD, DASL-HiCaP Among N1 pts only, ARPI MFS benefit: ◾️STAMPEDE M0: HR 0.49, 95%CI 0.38-0.64 ◾️ENZARAD: HR 0.43, 95%CI 0.20-0.92 ◾️DASL-HiCaP: HR 0.39, 95%CI 0.19-0.81